Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.2 (
guanylate cyclase
)
8,497
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to investigate the role of NO-cGMP pathway in NMDA-induced
NGF
mRNA expression by T67 astrocytoma cells. Levels of nitrite, a breakdown product of NO, in supernatants of NMDA-treated astrocytoma cells were significantly higher compared with control cells, this effect being reversed by the specific NO synthase inhibitor L-NAME. Furthermore,
NGF
mRNA expression was induced by NMDA treatment, this effect being inhibited by pretreating cells with L-NAME. Moreover, methylene blue, an inhibitor of NO biological activity at
guanylate cyclase
level, inhibited NMDA-induced
NGF
mRNA expression and this effect was reversed by dbt2-cGMP. These findings suggest that NO-cGMP pathway mediates the synthesis of
NGF
mRNA.
...
PMID:NMDA-dependent NGF mRNA expression by human astrocytoma cells is mediated by nitric oxide. 769 84
We investigated whether Angiotensin II type 2 (AT2) receptor activation was involved in
NGF
-induced nerve regeneration.
NGF
-mediated neurite outgrowth in cultured dorsal root ganglia (DRG) cells was significantly inhibited by AT2 receptor antagonist (PD123,319) treatment. AT2 receptor knockdown also inhibited
NGF
-mediated neurite outgrowth. To determine the mechanisms, we analyzed the NO-cGMP pathway. The cGMP analog increased
NGF
-mediated nerve elongation, which inhibited by PD123,319. Furthermore, soluble
guanylate cyclase
expression was significantly less in
NGF
and PD123,319 treatment DRG than in
NGF
treatment alone. These results suggest that
NGF
-mediated neurite outgrowth is suppressed by AT2 receptor signaling via the NO-cGMP-PKG pathway.
...
PMID:Angiotensin II AT2 receptors regulate NGF-mediated neurite outgrowth via the NO-cGMP pathway. 2752 38